Talphera posted a net loss of $4.4 million for Q3 2025, up from $3.4 million a year ago. Revenue was minimal at $1,000. Operating expenses declined slightly, and the company held $21.3 million in cash and investments at quarter end.

Talphera posted a net loss of $3.5 million in Q2 2025, with zero revenue. Operating expenses were reduced year-over-year, driven by cost control measures. Cash and cash equivalents stood at $6.8 million at quarter-end.

Talphera reported $27,000 in revenue and a net loss of $2.6 million in Q1 2025, reflecting lower operating expenses compared to the prior year. The company made progress on its NEPHRO CRRT trial and secured the first tranche of a $14.8 million financing to support clinical development.

In Q4 2024, Talphera (formerly AcelRx) reported no revenue, reflecting the transition in its commercial strategy. The company significantly reduced its operating expenses to $3.0 million, down from $4.6 million a year earlier. As a result, the net loss narrowed to $1.87 million, compared to $4.52 million in Q4 2023. Cash and investments stood at $8.86 million at quarter end.

Talphera reported its third quarter 2024 financial results, highlighting progress in the NEPHRO CRRT study with activated screening sites and an expectation to complete the study next year. The company's cash and investments totaled $11.1 million as of September 30, 2024.

Talphera reported a net loss from continuing operations of $3.8 million for the second quarter of 2024. Patient screening has been initiated at multiple clinical sites for the NEPHRO CRRT registrational study.

Talphera reported a net loss from continuing operations of $4.0 million for the first quarter of 2024, compared to net income of $0.1 million for the same period in 2023. As of March 31, 2024, the company's cash and cash equivalents balance was $18.6 million.

Talphera, Inc. reported Q4 2023 financial results, highlighting a company transformation and focus on Niyad, with revenues of $0.3 million and a net loss of $4.5 million. The company completed a rebranding, secured $26 million in committed capital, and is advancing Niyad into a registrational trial.

AcelRx announced Niyad™ IDE approval by the FDA and plans to start its Niyad registrational study this quarter, with topline data expected mid-2024. The company reported cash and investments of $13.4 million as of September 30, 2023 and revenues of $0.1 million for the third quarter.

AcelRx reported its second quarter 2023 financial results, highlighting a focus on their late-stage product portfolio following the divestment of DSUVIA. They await the FDA's response to their Emergency Use Authorization (EUA) request for Niyad and are set to begin a registrational study in Q4 2023. The company closed a capital raise in July, gaining access to up to $26.3 million.

AcelRx Pharmaceuticals reported a net loss attributable to common shareholders of $8.2 million, or $0.75 per basic and diluted share, for the first quarter of 2023. The company closed the divestment of DSUVIA to Alora Pharmaceuticals and submitted a request for an Emergency Use Authorization for Niyad.

AcelRx Pharmaceuticals reported its Q4 2022 financial results, highlighting the divestment of DSUVIA to Alora Pharmaceuticals and progress in its Niyad™ nafamastat program. The company is focusing on late-stage assets and expects near-term corporate milestones by the end of Q2 2023, including an Emergency Use Authorization submission for Niyad and a New Drug Application for Fedsyra™.

AcelRx Pharmaceuticals reported a net loss of $6.9 million for Q3 2022. DSUVIA sales saw a significant increase of 217% compared to the same quarter in the previous year, reaching $0.5 million. The company is progressing with the development of Niyad™ and expects to submit an NDA for ephedrine pre-filled syringe by the end of the year.

AcelRx Pharmaceuticals reported Q2 2022 financial results, highlighting $0.6 million in net revenue, a 133% increase in DSUVIA sales compared to Q2 2021, and a significant $84.1 million gain on debt extinguishment. The company is focused on a potential Emergency Use Authorization for Niyad™ in 2023 and pre-filled syringe NDA submissions this year.

AcelRx Pharmaceuticals reported $0.4 million in net revenues for Q1 2022. The company is realigning its cost structure to focus on development, expecting $9 million in annual savings. DSUVIA sales continued to grow, with a 64% increase in commercial sales compared to the previous quarter.

AcelRx Pharmaceuticals reported its Q4 and full year 2021 financial results, with a focus on expanding its product portfolio and adapting to the evolving healthcare environment. DSUVIA unit sales saw significant growth in Q4, although net revenues were minimal due to a reserve for potential returns. The company is also advancing the development of Niyad™ and pre-filled syringe product candidates.

AcelRx Pharmaceuticals reported Q3 2021 total revenues of $1.9 million. The company had $48.7 million in cash and short-term investments as of September 30, 2021. AcelRx also announced the acquisition of Lowell Therapeutics, Inc. to expand its pipeline.

AcelRx Pharmaceuticals reported a net revenue of $0.4 million and a net loss of $9.9 million, or $0.08 per share for the second quarter of 2021. The company's cash and short-term investments balance was $55.3 million as of June 30, 2021. DSUVIA sales increased by 117% compared to Q1 2021.

AcelRx Pharmaceuticals reported $67.3 million in cash and short-term investments as of March 31, 2021. First quarter net revenues were $0.5 million, and net loss was $9.0 million, or $0.08 per share.

AcelRx Pharmaceuticals reported Q4 2020 net revenues of $0.7 million and a net loss of $8.9 million, or $0.10 per share. The company achieved several milestones, including Milestone C approval from the Department of Defense and expansion of U.S. military access to DSUVIA.

AcelRx Pharmaceuticals reported a net revenue of $1.4 million for the third quarter of 2020, with product sales contributing $1.3 million, a significant increase from the previous quarter. The company's net loss was $8.9 million, or $0.10 per share. Key achievements included a collaboration with Zimmer Biomet and expansion of DSUVIA's availability to the U.S. Department of Defense.

AcelRx Pharmaceuticals reported Q2 2020 net revenues of $2.9 million, which included $2.6 million related to the Zalviso agreement with Grünenthal. The company's net loss was $6.6 million, or $0.08 per share, compared to a net loss of $12.4 million, or $0.16 per share, for the second quarter of 2019. The company also achieved Milestone C approval from the Department of Defense and entered into an exclusive distribution agreement with Zimmer Biomet for dental surgeries.

AcelRx Pharmaceuticals reported first quarter 2020 financial results, highlighting the Milestone C approval for DSUVIA and the ongoing Tetraphase transaction. The company anticipates strong order volume from the U.S. Army and is integrating its commercial team with Tetraphase under a co-promotion agreement.

AcelRx Pharmaceuticals reported Q4 2019 net revenues of $0.5 million and a net loss of $14.4 million, or $0.18 per share. The company exceeded its 2019 goals for REMS-certified facilities and formulary approvals, with 166 and 148 respectively by year-end.